CA2531878A1 - Usage therapeutique de g53135-05 (fgf-20) en protection contre les rayonnements - Google Patents

Usage therapeutique de g53135-05 (fgf-20) en protection contre les rayonnements Download PDF

Info

Publication number
CA2531878A1
CA2531878A1 CA002531878A CA2531878A CA2531878A1 CA 2531878 A1 CA2531878 A1 CA 2531878A1 CA 002531878 A CA002531878 A CA 002531878A CA 2531878 A CA2531878 A CA 2531878A CA 2531878 A1 CA2531878 A1 CA 2531878A1
Authority
CA
Canada
Prior art keywords
radiation
polypeptide
subject
cells
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002531878A
Other languages
English (en)
Inventor
Enriquez Alvarez
Timothy K. Maclachlan
Bisni Narayanan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
Curagen Corporation
Enriquez Alvarez
Timothy K. Maclachlan
Bisni Narayanan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corporation, Enriquez Alvarez, Timothy K. Maclachlan, Bisni Narayanan filed Critical Curagen Corporation
Publication of CA2531878A1 publication Critical patent/CA2531878A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002531878A 2003-05-09 2004-05-10 Usage therapeutique de g53135-05 (fgf-20) en protection contre les rayonnements Abandoned CA2531878A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46935303P 2003-05-09 2003-05-09
US60/469,353 2003-05-09
US54430804P 2004-02-26 2004-02-26
US60/544,308 2004-02-26
PCT/US2004/014622 WO2005025489A2 (fr) 2003-05-09 2004-05-10 Usage therapeutique de g53135-05 (fgf-20) en protection contre les rayonnements

Publications (1)

Publication Number Publication Date
CA2531878A1 true CA2531878A1 (fr) 2005-03-24

Family

ID=34316216

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002531878A Abandoned CA2531878A1 (fr) 2003-05-09 2004-05-10 Usage therapeutique de g53135-05 (fgf-20) en protection contre les rayonnements

Country Status (5)

Country Link
EP (1) EP1660008A2 (fr)
JP (1) JP2007531702A (fr)
AU (1) AU2004271913A1 (fr)
CA (1) CA2531878A1 (fr)
WO (1) WO2005025489A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (fr) 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Procédés de traitement et de prévention du syndrome gi et de la réaction de greffe contre l'hôte
AU2013266069B2 (en) 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871029B (en) * 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
JP2000319193A (ja) * 1999-03-01 2000-11-21 Sumitomo Pharmaceut Co Ltd 抗がん療法または放射線による組織障害の予防及び／又は治療剤
US7056885B1 (en) * 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
AU7181101A (en) * 2000-07-03 2002-01-14 Curagen Corp Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
JP2007531702A (ja) 2007-11-08
EP1660008A2 (fr) 2006-05-31
WO2005025489A2 (fr) 2005-03-24
AU2004271913A1 (en) 2005-03-24
WO2005025489A3 (fr) 2008-09-04

Similar Documents

Publication Publication Date Title
Li et al. Zinc promotes functional recovery after spinal cord injury by activating Nrf2/HO-1 defense pathway and inhibiting inflammation of NLRP3 in nerve cells
Zhang et al. Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation
US8389468B2 (en) Approach to the treatment of compartment syndrome
EP3139949B1 (fr) Compositions comprenant un protéine de fusion de vip-elp pour l'utilisation dans le traitement de la fibrose kystique
PT1491208E (pt) Composições farmacêuticas contendo polipéptido líquidas estabilizadas
JPH04235135A (ja) 医薬組成物
KR20200020817A (ko) 글루카곤-유사-펩티드-2 (glp-2) 유사체의 투여를 위한 용량요법
PT91863B (pt) Processo de preparacao de uma preparacao farmaceutica a base de gama-interferao
US20020032153A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
EP2185581B1 (fr) Procédées et compositions utiles dans le traitement de la mucosite
Walsh et al. N-acetylcysteine administration in the critically ill
BR112021005858A2 (pt) formulações de análogos de peptídeo semelhante a glucagon 2 (glp-2)
US4916117A (en) Treatment of inflammation using alpha 1-antichymotrypsin
Ahmed et al. Combinatory effects of bone marrow-derived mesenchymal stem cells and indomethacin on adjuvant-induced arthritis in Wistar rats: roles of IL-1β, IL-4, Nrf-2, and oxidative stress
KR20170058384A (ko) 조기 난포 활성화의 방지 방법
CA2032859C (fr) Methode et compositions permettant de reduire ou de prevenir les effets secondaires associes a la steroidotherapie
ZA200603396B (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
CA2586213A1 (fr) Formulations, procedes de production et utilisations du fgf-20
US9616100B2 (en) Methods of use of HSP70 for increased performance or treatment of HSP70 related disorders
CA2566507A1 (fr) Utilisations prophylactiques et therapeutiques de fgf-20 en protection antirayonnement
CA2531878A1 (fr) Usage therapeutique de g53135-05 (fgf-20) en protection contre les rayonnements
US20050215473A1 (en) Prophylactic and therapeutic uses of FGF-20 in radiation protection
CN114555630A (zh) 用于治疗脊髓损伤和/或髓鞘再生的肽的全身施用
US20100189802A1 (en) Method for treatment of vascular hyperpermeability
US20230293640A1 (en) Compounds for the treatment of endotheliitis in context of virally caused diseases

Legal Events

Date Code Title Description
FZDE Dead